Haleon Pakistan Limited (PSX:HALEON)

Market Cap	97.62B
Revenue (ttm)	41.88B
Net Income (ttm)	5.96B
Shares Out	117.05M
EPS (ttm)	50.93
PE Ratio	16.38
Forward PE	13.82
Dividend	30.00 (3.60%)
Ex-Dividend Date	Nov 4, 2025

Volume	26,230
Average Volume	30,797
Open	836.00
Previous Close	834.07
Day's Range	825.01 - 844.00
52-Week Range	653.14 - 975.00
Beta	0.33
RSI	48.07
Earnings Date	Feb 6, 2026

About Haleon Pakistan

Haleon Pakistan Limited engages in the manufacture, marketing, and sale of consumer healthcare products in Pakistan, rest of Asia, Africa, Australia, North America, the Middle East, and Europe. The company offers oral health, pain relief, wellness and nutrition, and respiratory health products, as well as over-the-counter pharmaceutical products. It sells its products primarily under the Panadol, CaC-1000 Plus, Sensodyne, paradontax, T-Day, ENO, Hydrozole, Qalsium-D, and Voltral Emulgel brands. The company also exports its products to Vietnam, ...

• Industry: Pharmaceutical Preparations
• Founded: 2015
• Employees: 450
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HALEON

Financial Performance

In 2024, Haleon Pakistan's revenue was 37.21 billion, an increase of 17.70% compared to the previous year's 31.61 billion. Earnings were 4.58 billion, an increase of 359.85%.